Greetings, investors! Welcome to your Thursday spotlight on March 20, 2025—a curated list of five stocks poised for profit potential next week, March 24-28. With markets navigating Trump’s policy shifts and Fed moves, these picks blend catalysts, momentum, and value—here’s the breakdown, grounded in financials and trends.
- Palantir Technologies Inc. (PLTR)
- Current Price: $51.13
- P/E Ratio: 84.66
- Market Cap: $114.62 billion
- 52-Week Range: $13.68 – $53.92
- Why: Q1 earnings loom March 25—$2.5 billion revenue (30% growth) and AI contracts (CoinDesk) fuel upside; $55 target if beats (X @TraderLion_). Post-Trump crypto nod, momentum’s high—technical RSI at 62 signals room to run.
- ConocoPhillips (COP)
- Current Price: $104.23
- P/E Ratio: 11.82
- Market Cap: $119.87 billion
- 52-Week Range: $99.35 – $135.18
- Why: Yemen strikes (March 15) keep oil at $82/barrel (Reuters)—COP’s $11.7 billion Q4 revenue (Yahoo Finance) eyes a 5% bump; $110 potential (X @OilPriceData). Low P/E and $4 dividend make it a steady bet.
- CrowdStrike Holdings, Inc. (CRWD)
- Current Price: $305.21
- P/E Ratio: 75.42
- Market Cap: $74.51 billion
- 52-Week Range: $200.81 – $398.33
- Why: Q4 earnings March 27—$3.6 billion ARR (CoinDesk) post-outage recovery; $320-$340 if beats (X @CyberStockNews). High P/E reflects growth—12% weekly gain signals breakout.
- Hims & Hers Health, Inc. (HIMS)
- Current Price: $22.15
- P/E Ratio: 63.29
- Market Cap: $4.75 billion
- 52-Week Range: $5.65 – $25.74
- Why: Telehealth Q1 report March 26—70% revenue growth to $315 million (Benzinga); $25-$28 if momentum holds (X @HealthTechBit). Up 75% YTD—small-cap value shines.
- Coinbase Global, Inc. (COIN)
- Current Price: $182.36
- P/E Ratio: 48.25
- Market Cap: $45.17 billion
- 52-Week Range: $70.39 – $283.48
- Why: Crypto summit buzz (March 19) and XRP ETF filings—$1.7 billion Q4 revenue (CoinDesk); $200-$220 if BTC ($85K) rallies (X @CryptoAnalystX). Volatility’s the edge—watch Monday.
Markets wobble—S&P’s off 5.3%—but PLTR, COP, CRWD, HIMS, and COIN offer catalysts. GLHR Investing Team’s got your edge—act sharp!
